Skye Bioscience Reports $55.9M Net Loss for FY2025, Limited Cash Runway, and Clinical Trial Updates

summarizeSummary

Skye Bioscience reported a significant net loss of $55.9 million for fiscal year 2025 and a cash balance of $25.7 million, which is insufficient to fund its anticipated Phase 2b clinical trial, signaling urgent financing needs amidst ongoing clinical development.

check_boxKey Events

• Significant Net Loss Reported

  The company reported a net loss of $55.9 million for the full year ended December 31, 2025, a substantial increase from $26.6 million in 2024.

• Limited Cash Runway

  Cash, cash equivalents, and short-term investments totaled $25.7 million as of December 31, 2025. This capital is expected to fund operations only through Q4 2026, explicitly *excluding* the costs for the proposed Phase 2b clinical study and additional drug manufacturing.

• Clinical Development Updates

  Skye Bioscience initiated a higher-dose CBeyond Expansion Study (Part C) for nimacimab, with topline data expected in Q4 2026. The company also received FDA Type C meeting minutes, which are informing the design of its Phase 2b trial, evaluating both monotherapy and combination with incretin therapy.

• Phase 2a Combination Therapy Results

  Interim 52-week results for nimacimab plus semaglutide combination therapy showed a 22.3% mean weight loss with no plateau observed. The company also noted a differentiated weight maintenance profile during the off-treatment follow-up period.

auto_awesomeAnalysis

Skye Bioscience's financial results for fiscal year 2025 reveal a substantial net loss of $55.9 million, more than double the previous year, and a cash balance of $25.7 million. Critically, the company states this cash is only sufficient to fund operations through Q4 2026, *excluding* the anticipated costs for its proposed Phase 2b clinical study and additional drug manufacturing. This indicates an urgent need for significant capital in the near future, which will likely be highly dilutive given the company's current market valuation and ongoing losses. While the company reported progress in its CBeyond Expansion Study and FDA feedback for its Phase 2b design, the severe financial constraints pose a significant challenge to advancing its clinical pipeline.